Loading data for PCRX — first visit, this takes a few seconds.
Pacira BioSciences, Inc. (PCRX)
NasdaqGS: PCRX
· 即時價格 · USD
25.87
-0.48 (-1.82%)
收盤價： Sep 10, 2026, 3:59 PM
股價、關鍵數字和最新消息，都在這一頁。
Pacira BioSciences, Inc.（PCRX）股價、分析與資料
-1.82% (1D)
| 買價 | 18.64 |
| 市值 | 1.01B |
| 營收 (ttm) | 746M |
| 淨利（ttm） | 14.6M |
| 0.27 | |
| 0.35 | |
| 72.36 | |
| 7.37 | |
| P/B (ttm) | 1.50 |
| P/S (ttm) | 1.34 |
| 財報日期 | Nov 5, 2026 |
| 賣價 | 33.1 |
| 成交量 | 381,579 |
| 20 日平均成交量 | 565,475 |
| 開盤價 | 25.98 |
| 前收盤價 | 26.35 |
| 當日區間 | 25.68 - 26.41 |
| 52 週範圍 | 18.80 - 27.66 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | n/a |
| 除息日 | n/a |
關於 PCRX
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and kne...
完整的公司簡介財報驚奇
Pacira BioSciences 已於 Aug 4, 2026 公布季度財報：
- 營收為 $192.4M 低於預期 $0, 年增 6.24% 成長.
- 每股盈餘為 0.73 超出預期 0.08, 年增 -1.35% 下滑.
第 1 頁，共 2 頁